Clinical Research in Southampton
Southampton Children's Hospital

A A A Text only | Accessibility | Privacy and cookies

Home
About the Trust
Our services
Patients and visitors
Our hospitals
Education
Research
Working here
Contact us

Browse site A to Z

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Search results

Go To Advanced Search

Search

RPACEBOM - Bleomycin-Cyclophosphamide-Doxorubicin-Etoposide-Methotrexate-Prednisolone-Rituximab-Vincristine

Description: Chemotherapy Protocol LYMPHOMA BLEOMYCIN-CYCLOPHOSPHAMIDE-DOXORUBICIN-ETOPOSIDE-METHOTREXATEPREDNISOLONE-RITUXIMAB-VINCRISTINE Regimen (RPACEBOM) Lymphom
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/RPACEBOM-Bleomycin-Cyclophosphamide-Doxorubicin-Etoposide-Methotrexate-Prednisolone-Rituximab-Vincristine.pdf

Pembrolizumab_400mg (lymphoma)

Description: Chemotherapy Protocol LYMPHOMA Pembrolizumab (400mg) Regimen • Lymphoma – Pembrolizumab (400mg) Indication • Pembrolizumab is indicated for relapsed or refractory classical Hodgkin lymphoma in
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Pembrolizumab-400mg.pdf

Pembrolizumab_200mg (lymphoma)

Description: Chemotherapy Protocol LYMPHOMA Pembrolizumab (200mg) Regimen • Lymphoma – Pembrolizumab (200mg) Indication • Pembrolizumab is indicated for relapsed or refractory classical Hodgkin lymphoma in
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Pembrolizumab-200mg.pdf

Nivolumab (lymphoma)

Description: Chemotherapy Protocol LYMPHOMA Nivolumab Regimen • Lymphoma – Nivolumab Indication • Nivolumab is recommended as an option for treating relapsed or refractory classical Hodgkin
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Nivolumab.pdf

Nivolumab 240mg (lymphoma)

Description: Chemotherapy Protocol LYMPHOMA Nivolumab (240mg-14 days) Regimen • Lymphoma – Nivolumab (240mg-14 days) Indication • Nivolumab is recommended as an option for
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Nivolumab-240mg.pdf

ABVD – Bleomycin-Dacarbazine-Doxorubicin-Vinblastine Ver 1.2

Description: Chemotherapy Protocol LYMPHOMA BLEOMYCIN-DACARBAZINE-DOXORUBICIN-VINBLASTINE (ABVD) Regimen Lymphoma – ABVD-Bleomycin-Dacarbazine-Doxorubicin-Vinblastine
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/ABVD-–-Bleomycin-Dacarbazine-Doxorubicin-Vinblastine-Ver-1.2.pdf

Doxorubicin-Olaratumab

Description: Chemotherapy Protocol SARCOMA DOXORUBICIN-OLARATUMAB Regimen • Sarcoma – Doxorubicin-Olaratumab Indication • In combination with doxorubicin for the first line treatment of advanced
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Sarcoma/Doxorubicin-Olaratumab.pdf

MyelomaRCDCyclophosphamideDexamethasoneLenalidomidel(RCD)Ver1

Description: Chemotherapy Protocol MULTIPLE MYELOMA RCD-CYCLOPHOSPHAMIDE-DEXAMETHASONE-LENALIDOMIDE There are multiple versions of this protocol in use. Please ensure you have
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/MyelomaRCDCyclophosphamideDexamethasoneLenalidomidelRCDVer1.pdf

Lenalidomide

Description: Chemotherapy Protocol MULTIPLE MYELOMA LENALIDOMIDE Regimen • Multiple Myeloma – Lenalidomide Indication • Lenalidomide is recommended, within its licensed indication, as an option for
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/Lenalidomide.pdf

IRD(40)-Dexamethasone_40_Ixazomib-Lenalidomide

Description: Chemotherapy Protocol Myeloma IRD (40) - Dexamethasone (40)-Ixazomib-Lenalidomide Regimen • Myeloma – IRD (40) - Dexamethasone (40)-Ixazomib-Lenalidomide Indication • Ixazomib and lenalidomide
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/IRD40-Dexamethasone-40-Ixazomib-Lenalidomide.pdf

601 to 610 of 672

Previous … 59 60 61 62 63 … Next